{"denoms":[{"counts":[{"groupId":"BG000","value":"256"},{"groupId":"BG001","value":"257"},{"groupId":"BG002","value":"250"},{"groupId":"BG003","value":"763"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W). Eligible participants who stopped the initial course of pembrolizumab with Stable Disease (SD) or better but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.","id":"BG000","title":"Pembrolizumab Monotherapy (Pembro Mono)"},{"description":"Participants received pembrolizumab 200 mg Q3W plus cisplatin 80 mg/m\\^2 Q3W plus 5-fluorouracil (5-FU) 800 mg/m\\^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m\\^2 twice a day (BID) on Days 1-14 Q3W could be substituted for 5-FU per local guidelines. Eligible participants who stopped the initial course of pembrolizumab with Stable Disease (SD) or better but progressed after discontinuation may have been able to initiate a second course of pembrolizumab for up to 17 cycles (up to approximately 1 additional year) at the investigator's discretion.","id":"BG001","title":"Pembrolizumab + SOC Chemotherapy (Pembro Combo)"},{"description":"Participants received placebo IV Q3W plus cisplatin 80 mg/m\\^2 Q3W plus 5-FU 800 mg/m\\^2/day IV infusion on Days 1-5 Q3W. Capecitabine 1000 mg/m\\^2 BID on Days 1-14 Q3W could be substituted for 5-FU per local guidelines.","id":"BG002","title":"Placebo + SOC Chemotherapy (SOC)"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.6","value":"59.9"},{"groupId":"BG001","spread":"11.6","value":"60.9"},{"groupId":"BG002","spread":"12.7","value":"60.7"},{"groupId":"BG003","spread":"12.0","value":"60.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"71"},{"groupId":"BG003","value":"209"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"180"},{"groupId":"BG001","value":"195"},{"groupId":"BG002","value":"179"},{"groupId":"BG003","value":"554"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"46"},{"groupId":"BG003","value":"145"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"206"},{"groupId":"BG001","value":"196"},{"groupId":"BG002","value":"197"},{"groupId":"BG003","value":"599"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"19"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"29"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"71"},{"groupId":"BG002","value":"67"},{"groupId":"BG003","value":"207"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"13"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"164"},{"groupId":"BG001","value":"167"},{"groupId":"BG002","value":"154"},{"groupId":"BG003","value":"485"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"22"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"5"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"148"},{"groupId":"BG001","value":"148"},{"groupId":"BG002","value":"147"},{"groupId":"BG003","value":"443"}]}],"title":"Europe/North America/Australia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"61"},{"groupId":"BG003","value":"187"}]}],"title":"Asia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"42"},{"groupId":"BG003","value":"133"}]}],"title":"Rest of the World"}],"description":"Participants were stratified according to geographic region of enrolling site:\n\nEurope (including Israel)/North America/Australia, Asia (including East Asia \\[South Korea, Hong Kong, Taiwan\\], South East Asia \\[Malaysia\\], Thailand, Singapore, Japan), or Rest of the World (including South America).","paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"35"}],"title":"Locally advanced"},{"measurements":[{"groupId":"BG000","value":"245"},{"groupId":"BG001","value":"243"},{"groupId":"BG002","value":"235"},{"groupId":"BG003","value":"723"}],"title":"Metastatic"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"5"}],"title":"Missing"}]}],"description":"Participants were stratified according to gastric cancer disease status as either locally advanced unresectable or metastatic disease.","paramType":"COUNT_OF_PARTICIPANTS","title":"Disease Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"97"},{"groupId":"BG001","value":"98"},{"groupId":"BG002","value":"95"},{"groupId":"BG003","value":"290"}],"title":"5-FU"},{"measurements":[{"groupId":"BG000","value":"159"},{"groupId":"BG001","value":"159"},{"groupId":"BG002","value":"155"},{"groupId":"BG003","value":"473"}],"title":"Capecitabine"}]}],"description":"Participants receiving SOC chemotherapy were stratified according to fluoropyrimidine treatment (5-FU or capecitabine).","paramType":"COUNT_OF_PARTICIPANTS","title":"Fluoropyrimidine Treatment","unitOfMeasure":"Participants"}]}